TY - JOUR
T1 - Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas
AU - Orita, Hiroyuki
AU - Maehara, Yoshihiko
AU - Anai, Hideaki
AU - Baba, Hideo
AU - Kusumoto, Hiroki
AU - Korenaga, Daisuke
AU - Sugimachi, Keizo
PY - 1994/1/1
Y1 - 1994/1/1
N2 - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.
AB - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0028355797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028355797&partnerID=8YFLogxK
U2 - 10.1002/ssu.2980100215
DO - 10.1002/ssu.2980100215
M3 - Article
C2 - 7914378
AN - SCOPUS:0028355797
VL - 10
SP - 135
EP - 139
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 2
ER -
